Recent News

• 02.27.2025 - MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
• 02.26.2025 - MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
• 02.24.2025 - MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
• 02.18.2025 - MAIA Biotechnology Announces Private Placement of $2,715,000
• 02.04.2025 - MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
• 01.10.2025 - MAIA Biotechnology to Present at Biotech Showcase 2025
• 01.07.2025 - MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Recent Filings

• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 8-K Current report
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities